Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvoPAR-Breast01 first-line trial of saruparib + camizestrant in BRCA1/2- or PALB2-mutated HR-positive HER2-negative advanced breast cancer
CTR20244809Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of saruparib, camizestrant in breast cancer, sponsored by AstraZeneca. Started Mar 2025; status: active.
02
Drugs
saruparibcamizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20244809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244809.